Adverse effects of growth hormone replacement therapy in children;Efeitos adversos da reposição de hormônio do crescimento em crianças

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 55, Issue 8, 2011, Pages 559-565

  Souza, Flavio Moutinho ^a   Collett Solberg, Paulo Ferrez ^b  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Growth hormone; Gynecomastia; Intracranial hypertension; Pediatrics; Scoliosis; Short stature; Side effects

Indexed keywords

HUMAN GROWTH HORMONE;

ADOLESCENT; CHILD; GROWTH DISORDER; HORMONE SUBSTITUTION; HUMAN; REVIEW;

ADOLESCENT; CHILD; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS;

EID: 84855445461     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302011000800009     Document Type: Review

References (58)

1. Fradkin, JE. Creutzfeldt-Jakob disease in pituitary growth hormone recipients. Endocrinologist. 1993;3:108-14.
2. Richmond E, Rogol AD. Current indications for growth hormone therapy in children and adolescents. Endocr Dev. 2010;18:92-108.
3. Ogilvy-Stuart AL. Growth hormone defciency (GHD) from birth to 2 years of age: diagnostic specifcs of GHD during the early phase of life. Horm Res. 2003;60(suppl 1):2-9.
4. Ali O, Banerjee S, Kelly D F, Lee PD. Management of type 2 diabetes mellitus associated with pituitary gigantism. Pituitary. 2007;10(4):359-64.
5. Vicens-Calvet E, Seijo G, Potau N, de los Llanos Moreno M, Car-rascosa A. Efectividad de la hormona de crecimiento recombinante en el défcit de talla debido a retraso de crecimiento intrau-terino. Med Clin (Barc). 1999;112(16):601-5.
6. Hansen BR, Haugaard SB, Jensen FK, Jensen JE, Andresen L, Iversen J, et al. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism. HIV Med. 2010;11(4):266-75.
7. Cutfeld WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Cha-telain P, Ranke MB, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000;355(9204):610.
8. Acharya SV, Gopal RA, Bandgar TR, Menon PS, Shah NS. Prepu-bertal gynecomastia a rare complication of growth hormone therapy. Indian J Pediatr. 2010;77(4):443-4.
9. Malozowski S, Stadel BV. Prepubertal gynecomastia during growth hormone therapy. J Pediatr. 1995;126(4):659-61.
10. Loder RT. Slipped capital femoral epiphysis. Am Fam Physician. 1998;57(9:)2135-42.
11. Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic in-tracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68(Suppl. 5):41-7.
12. Peck D. Slipped capital femoral epiphysis: diagnosis and management. Am Fam Physician. 2010;82(3):258-62.
13. de Andrade AC, Longui CA, Damasceno FL, Santili C. Southwick's angle determination during growth hormone treatment and its usefulness to evaluate risk of epiphysiolysis. J Pediatr Orthop B. 2009;18(1):11-5.
14. Collett-Solberg P F, Liu G T, Satin-Smith M, Katz LL, Moshang T. Pseudopapilledema and congenital disc anomalies in growth hormone defciency. J Ped Endocrinol Metabol. 1998;11,261-5.
15. Watanabe S, Mizuno S, Oshima LH, Tsunematsu Y, Fujimoto J, Ko-miyama A. Leukemia and other malignancies among GH users. J Pediatr Endocrinol. 1993;6(1):99-108.
16. Seif AE. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 2011;204(5):227-44.
17. Allen DB. Safety of human growth hormone therapy: Current topics. J Pediatr. 1996;128(5 pt 2):S8-13.
18. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87(7):3136-41.
19. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91:3494-8.
20. Nishio S, Morioka T, Inamura T, Takeshita I, Fukui M, Sasaki M, et al. Radiation-induced brain tumours: potential late complications of radiation therapy for brain tumours. Acta Neurochir (Wien). 1998;140:763-70.
21. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab. 2011;96:2756-61.
22. Burgers AM, Biermasz NR, Schoones JW, Pereira AM, Renehan AG, Zwahlen M, et al. Meta-analysis and dose-response metare-gression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab. 2011;96(9):2912-20.
23. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kague-lidou F, Rey G, et al. Long-term mortality after recombinant growth hormone treatment for isolated childhood short stature: report of the French SAGhE study. Endocr Rev. 2011;32(03_ MeetingAbstracts):LB-5.
24. Agence Française de Sécurité Sanitaire dês Produits de Santé. Hormone de Croissance synthétique (somatropine recombi-nante): Premiers résultats de l'étude épidémiologique sur la tolérance à long terme. 2010. Available at: http://www.afssaps.fr/Infos-de-securite/Communiques-Points-presse/Hormone-de--Croissance-synthetique-somatropine-recombinante-Premiers--resultats-de-l-etude-epidemiologique-sur-la-tolerance-a-long--terme-Communique. Accessed on: Sept 4, 2011.
25. Carel JC, Coste J. Information concerning the communication of preliminary results of the French SAGhE study. 2010. Available at: http://saghe.aphp.fr/site/IMG/pdf/Information_concerning_the_communication_of_preliminary_results_of_the_French_SAGhE_study.pdf. Accessed on: Sept 4, 2011.
26. FDA drug safety communication: ongoing safety review of re-combinant human growth hormone (somatropin) and possible increased risk of death. 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm237773.htm. Accessed on: Sept 4, 2011.
27. Oliveira JO, Siviero-Miachon AA, Spinola-Castro AM, Belangero VMS, Guerra-Junior G. Baixa estatura na doença renal crônica: fsiopatologia e tratamento com hormônio de crescimento. Arq Bras Endocrinol Metab. 2008;52(5):783-91.
28. Mahan JD, Warady BA. Consensus committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol. 2006;21:917-30.
29. Kaufman DB. Growth hormone and renal osteodystrophy: a case report. Pediatr Nephrol. 2008;12:157-9.
30. Blethen SL, Allen DB, Graves D, August G, Moshang T, Rosenfeld R. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab. 1996;81(5):1704-10.
31. Fine RN, Ho M, Tejani A, Blethen S. Adverse events with rhGH treatment of patients with chronic renal insuffciency and end-stage renal disease. J Pediatr. 2003;142:539-45.
32. Wiihl E, Haffner O, Gretz N, Offner G, van't Hoff WG, Broyer M, et al.; The European Study Group on Growth Hormone Treatment in Short Children with Nephropathic Cystinosis. Treatment with recombinant human growth hormone in short children with ne-phropatic cystinosis: no evidence for increased deterioration rate of renal function. Pediatr Res. 1998;43:484-8.
33. Hokken-Koelega AC, Stijnen T, de Ridder MA, de Muinck Keizer--Schrama SM, Wolff ED, de Jong MC, et al. Growth hormone treatment in growth-retarded adolescents after renal transplant. Lancet. 1994;343:1313-7.
34. Fine RN, Stablein D, Cohen AH, Tejani A, Kohaut E. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int. 2002;62:688-96.
35. Ricotti S, Petrucci L, Carenzio G, Klersy C, Calcaterra V, Larizza D, et al. Prevalence and incidence of scoliosis in Turner syndrome: a study in 49 girls followed-up for 4 years. Eur J Phys Rehabil Med. 2011;47(3):447-53.
36. Bourguignon J P, Piérard GE, Ernould C, Heinrichs C, Craen M, Ro-chiccioli P, et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet. 1993;341(8859):1505-6.
37. Piérard GE, Piérard-Franchimont C, Nikkels A, Nikkels-Tassoudji N, Arrese JE, Bourguignon J P. Naevocyte triggering by recombi-nant human growth hormone. J Pathol. 1996;180(1):74-9.
38. Wyatt D. Melanocytic nevi in children treated with growth hormone. Pediatrics. 1999;104(4 Pt 2):1045-50.
39. Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of re-combinant human growth hormone in turner syndrome. J Clin Endocrinol Metab. 2008;93:344-51.
40. Albertsson-Wikland K, Karlberg J. Postnatal growth of children born small for gestational age. Acta Paediatr Suppl. 1997;423:193-5.
41. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P. International small for gestational age advisory board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics. 2003;111:1253-61.
42. Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippol-dt TB, et al.; American Association of Clinical Endocrinologists Growth Hormone Task Force 2003. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children-2003 update. Endocr Pract. 2003;9:64-73.
43. European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products (CPMP) 2003 Norditro-pin. Available at: http://www.ema.europa.eu/pdfs/human/referral/norditropin/347803en.pdf. Accessed on: Sept 4, 2011.
44. Boguszewski MCS, Mericq V, Bergada I, Damiani D, Belgorosky A, Gunczler P, et al. Latin American Consensus: Children Born Small for Gestational Age. BMC Pediatr. 2011;11:66.
45. Einfeld SL, Kavanagh SJ, Smith A, Evans EJ, Tonge BJ, Ta-ffe J. Mortality in Prader-Willi Syndrome. Am J Ment Retard. 2006;111(3):193-8.
46. Tauber M, Diene G, Molinas C, Hébert M. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A. 2008;146(7):881-7.
47. Lee PDK. Growth hormone and mortality in Prader Willi syndrome. GGH Journal. 2006;22(2):17-23.
48. van Wijngaarden rfa de L, Siemensma EPC, Festen DAM, Otten BJ, van Mil EGAH, Rotteveel J, et al. Effcacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2009;94:4205-15.
49. Nakamura Y, Nagai T, Iida T, Ozeki S, Nohara Y. Epidemiological aspects of scoliosis in a cohort of Japanese patients with Prader--Willi syndrome. Spine J. 2009;9(10):809-16.
50. Nagai T, Obata K, Ogata T, Murakami N, Katada Y, Yoshino A, et al. Growth hormone therapy and scoliosis in patients with Prader--Willi syndrome. Am J Med Genet A. 2006;140(15):1623-7.
51. West LA, Ballock R T. High incidence of hip dysplasia but not slipped capital femoral epiphysis in patients with Prader-Willi syndrome. J Pediatr Orthop. 2004;24(5):565-7.
52. Poussa M, Schlenzka D, Yrjönen T. Body mass index and slipped capital femoral epiphysis. J Pediatr Orthop B. 2003;12(6):369-71.
53. Murray AW, Wilson NI. Changing incidence of slipped capital femoral epiphysis: a relationship with obesity? J Bone Joint Surg Br. 2008;90(1):92-4.
54. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al.; On behalf of the 2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93:4210-17.
55. Kemp S F, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, et al. Eff-cacy and safety results of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab. 2005;90:5247-53.
56. Grossmann KS, Rosário M, Birchmeier C, Birchmeier W. The tyro-sine phosphatase Shp2 in development and cancer. Adv Cancer Res. 2010;106:53-89.
57. Liu X, Qu CK. Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis. J Signal Transduct 2011;2011:195-239. Epub 2011 Jun 7.
58. Noordam C. Growth hormone and the heart in Noonan syndrome. Horm Res. 2009;72 Suppl 2:49-51.